Concord Biotech Completes ANVISA Inspection At Limbasi Facility; Shares Up Marginally

Mumbai, June 12: Concord Biotech announced the successful completion of an inspection conducted by Brazil’s health regulatory agency ANVISA at its API manufacturing facility located in Limbasi.

The company stated that the inspection was conducted between June 8 and June 12, 2026, and concluded successfully, according to an exchange disclosure filed on June 12, 2026.

According to the filing, the successful inspection marks a milestone in the company’s international regulatory and manufacturing expansion strategy. Concord Biotech said the development reinforces its commitment to quality standards and strengthens its global manufacturing footprint.

The company further noted that the inspection outcome is expected to support broader access to regulated pharmaceutical markets and enhance the reach of its active pharmaceutical ingredients across global geographies.

As per the disclosure, the successful regulatory review also advances the company’s international expansion strategy by strengthening compliance credentials in overseas markets.

Stock Market Snapshot

Concord Biotech share price traded marginally higher following the company’s announcement regarding the successful completion of the ANVISA inspection.

As of 1:54 PM IST on June 12, 2026, shares of Concord Biotech Ltd were trading at ₹1,346.10 on the NSE, up 0.21% from the previous close of ₹1,343.30.

The market reaction remained measured as investors assessed the significance of the regulatory milestone for the company’s API export operations and international market access.

The Concord Biotech share price movement reflected continued investor focus on regulatory compliance, manufacturing standards and export-oriented pharmaceutical businesses.

Company Background

Concord Biotech Ltd operates in the pharmaceutical and biotechnology sector with a focus on fermentation-based active pharmaceutical ingredients and formulations.

The company supplies APIs to regulated and semi-regulated markets across multiple international geographies and continues to expand its manufacturing and compliance infrastructure.

Regulatory inspections by international health authorities form a critical component of pharmaceutical export operations, particularly for companies supplying APIs to overseas customers.

Concord Biotech has continued to strengthen its manufacturing capabilities and quality systems as part of its long-term global growth strategy.

Conclusion

The successful completion of the ANVISA inspection at the Limbasi API manufacturing facility represents an important regulatory development for Concord Biotech.

The outcome is expected to support the company’s international market access and reinforce its compliance profile within regulated pharmaceutical markets. Investors monitored the announcement for its implications on the company’s export operations and global manufacturing presence.

Source:

• https://www.nseindia.com/get-quote/equity/CONCORDBIO/Concord-Biotech-Limited
• https://nsearchives.nseindia.com/corporate/CONCORD_12062026133511_Intimation_ANVISA.pdf